BETAFECTIN EFFICACY TO BE EXAMINED v. SURGICAL SITE INFECTIONS
Executive Summary
BETAFECTIN EFFICACY TO BE EXAMINED v. SURGICAL SITE INFECTIONS in an upcoming Phase III trial of the beta glucan polymer under development by Alpha-Beta Technology. The Phase III trial will enroll 900 patients with major elective gastrointestinal surgery at 25 to 30 centers. Patients will be randomized to placebo, .5 mg/kg Betafectin, or 1 mg/kg Betafectin. Alpha-Beta projects that the study will begin by the end of calendar 1994.